Fighting variants of COVID-19

As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop and manufacture safe and effective vaccines. To date, two vaccines have been granted Emergency Use Authorization (EUA) in the United States by the U.S. Food and Drug Administration (FDA). Another vaccine candidate has been submitted for an EUA and several others have made substantial progress in their clinical development programs. Meanwhile, Americans across the country have now started to be vaccinated. While this is a tremendous achievement, biopharmaceutical companies are not done fighting COVID-19.